

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following descriptions best reflects the mechanism of action of the novel agent relatlimab?
 - Anti-PD-1/PD-L1 antibody
 - Anti-LAG-3 antibody
 - Bispecific HER2-targeting antibody
 - Claudin 18.2-targeting monoclonal antibody
 - TROP2-directed antibody-drug conjugate
- Primary results from the Phase II DESTINY-CRC02 study evaluating 2 doses of trastuzumab deruxtecan (T-DXd) for patients with HER2-overexpressing/amplified metastatic colorectal cancer (mCRC), which showed promising antitumor activity with T-DXd at both 5.4 and 6.4 mg/kg doses, established which of the following dosages as the optimal single-agent dose for this population due to its positive risk-benefit profile?
 - 5.4 mg/kg
 - 6.4 mg/kg
 - Neither a nor b
- In the CIRCULATE-Japan study, which outcome was observed regarding disease-free survival (DFS) and circulating tumor DNA (ctDNA) dynamics?
 - Sustained ctDNA clearance was associated with superior DFS, and the DFS benefit was maintained at 24 months
 - Transient ctDNA clearance was associated with improved DFS, and the DFS benefit was sustained at 24 months
 - There was no difference in DFS outcomes between patients with sustained and transient ctDNA clearance
- Which of the following statements best characterizes overall survival (OS) observations with TAS-102 and bevacizumab compared to TAS-102 monotherapy in the Phase III SUNLIGHT trial for patients with refractory mCRC?
 - OS was equivalent with both regimens
 - OS improved with TAS-102/bevacizumab
 - OS improved with TAS-102 monotherapy
- Which of the following agents led to improved OS compared to placebo in the Phase III FRESCO-2 trial for patients with advanced, chemotherapy-refractory colorectal cancer?
 - Sotorasib
 - Fruquintinib
 - Pembrolizumab